About us

We are innovative, dedicated, and we care. We improve global healthcare through better access to medicine.​

Today, the Abacus Medicine Group is a large and growing entity, where diversity is treasured. We work as a team, and our commercial activities provide jobs, careers, and livelihoods for thousands of people in dozens of countries.

As the Abacus Medicine Group grows, so does our societal impact. We recognise our obligation to our stakeholders and to the wider society. This is reflected in our Sustainability efforts.

In the Abacus Medicine Group, we are highly conscious of our contribution to society. This has been the case ever since the family business was founded by father and son in 2004.

In the Abacus Medicine Group, we are proud to serve a purpose beyond ourselves.

When we compete in the market, we improve availability and reduce prices of life-critical medicines, so they become more widely available. Our parallel distribution business helps us achieve exactly that. And with Abacus Medicine Pharma Services, and our Dutch pharmaceutical wholesaler, Pluripharm, we provide better access to pharmaceutical products for even more patients, doctors and pharmaceutical manufacturers.

The Abacus Medicine Group has grown fast since the beginning, and as we grow, we are able to make an ever-increasing contribution. To us, this is the hallmark of a sustainable business model.

We strive to uphold these values, both to society and to our external and internal relations.
Therefore, we have created our own compliance framework.

In September 2024, the Abacus Medicine Group celebrated 20 years of continued growth and successfully providing better access to healthcare.

In just two decades, we have developed in ways that are not often seen in Danish-founded companies. Watch the video to experience some of the milestones we have reached since it all started back in 2004.

Management & Board of Directors

The Abacus Medicine Group is headed by our Board of Directors and the Executive Management team.

Sustainability

We want to do better where it really matters.

Sustainability in the Abacus Medicine Group is an ongoing and never-ending process. From year to year, gradual changes in our business landscape and in the priorities of our stakeholders will affect our Sustainability priorities.

These are some of the areas we’re working with:

We are expanding our coverage of ESG metrics and adjusting some existing ones to enhance our reporting framework.

Building on previous efforts, we continue to explore ways to reduce the environmental impact of our transportation activities.

We take a holistic view of our entire production process, overseeing operations from start to finish across all production sites.

We seek to enforce the Supplier Code of Conduct with all external suppliers while formalising related processes within the organisation.

We continually expand our efforts globally, working toward implementing our comprehensive Diversity & Inclusion strategy across the entire Abacus Medicine Group.

We actively engage in the communities we’re a part of and seek to build a strong one of our own; a good and caring workplace.

Ein kleiner Junge pflanzt einen kleinen Baum. Ein Mann hilft ihm dabei.

Sustainability Report 2024

Employees, environment and more. How did we progress and what are our plans?

Sustainability Policy

Sustainability in the Abacus Medicine Group is rooted in the UN Sustainable Development Goals.

Timeline

The Abacus Medicine Group is a young group of companies that has come far in a short time.
Browse through the main events of our journey below.

2004

Abacus Medicine is founded by father and son: John and Flemming Wagner

2004

2006

First deliveries to Danish pharmacies and hospitals

2006

2009

Abacus Medicine becomes the largest parallel importer of medicine to the Danish hospital network

2009

2010

Beyond borders: Sweden becomes our first export market

2010

2012

Abacus Medicine Hungary is established and we have our first deliveries to Germany

2012

2014

First deliveries in the Netherlands

2014

2015

First deliveries in the UK and in Austria

2015

2016

Revenue exceeds 1 billion DKK

2016

2017

First deliveries in France and Finland and the acquisition of Aposave (now Abacus Medicine Pharma Services)

2017

2018

Production begins at new, second site in Alkmaar in the Netherlands

2018

2019

Chr. Augustinus Fabrikker joins as strategic investor

2019

2020

Acquisition of Pluripharm and we reach 1,000 employees

2020

2022

Combined revenue of the group’s business units surpasses 1,000,000,000 euros

2022

2024

The Abacus Medicine Group celebrates 20 years of providing better access to healthcare

2024

Whisteblower Scheme

The Abacus Medicine Group has established a Whistleblowing Scheme in order to allow the reporting of potential violations of the law and serious violations of internal company policy and procedures.